Etrolizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Etrolizumab?
Monoclonal antibody
Type Whole antibody
Source Humanized (from rat)
Target integrin α7β7
Identifiers
CAS Registry Number 1044758-60-2 N
ATC code None
UNII I2A72G2V3J YesY
Chemical data
Formula C6396H9874N1702O2010S42
Molecular mass 144.1 kDa
 N (what is this?)  (verify)

Etrolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory bowel disease.[1]

Etrolizumab was developed by Genentech.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab" (PDF). American Medical Association.